Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 May 9

PMID 32380650

Citations 10

Authors

Min Jung Kim

Jong Rip Choi

Nara Tae

Tae Min Wi

Kristine M Kim

Dae Hee Kim

Eung Suk Lee

Affiliations

Soon will be listed here.

Abstract

Mucin1 (MUC1) is aberrantly glycosylated and overexpressed in various cancers, and it plays a crucial role in cancerogenesis. MUC1 is a type I membranous protein composed of α and β subunits. MUC1-α can be cleaved in cancers, exposing MUC1-β (MUC1-C). MUC1-C is involved with multiple cancer cellular functions, which makes it an attractive target for cancer treatment. However, its multifunctional mechanisms have not been fully elucidated and there has not been a successful therapeutic development against MUC1-C. Through a phage display process, we isolated the specific antibodies for the extracellular domain of MUC1-C. The relevant full IgG antibodies were produced successfully from mammalian cells and validated for their MUC1-C specificities through ELISA, dual FACS analysis, BLI assay, and confocal image analysis. In the comparison with reference antibody, elected antibodies showed characteristic bindings on target antigens. In the functionality assessment of high-ranking antibodies, SKM1-02, -13, and -20 antibodies highly inhibited invasion by triple-negative breast cancer (TNBC) cells and the SKM1-02 showed strong growth inhibition of cancer cells. Our results showed that these MUC1-C specific antibodies will be important tools for the understanding of MUC1 oncogenesis and are also highly effective therapeutic candidates against human breast cancers, especially TNBC cells.

Citing Articles

MUC1 and MUC16: critical for immune modulation in cancer therapeutics.

Chen X, Sandrine I, Yang M, Tu J, Yuan X Front Immunol. 2024; 15:1356913.

PMID: 38361923 PMC: 10867145. DOI: 10.3389/fimmu.2024.1356913.

The multiple roles of C-type lectin receptors in cancer.

Li Q Front Oncol. 2023; 13:1301473.

PMID: 38090489 PMC: 10715585. DOI: 10.3389/fonc.2023.1301473.

An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1.

Aftab F, Rodriguez-Fuguet A, Silva L, Kobayashi I, Sun J, Politi K Br J Cancer. 2023; 128(9):1647-1664.

PMID: 36810913 PMC: 10133251. DOI: 10.1038/s41416-023-02196-z.

Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review.

Hosseini M, Seyedpour S, Khodaei B, Loghman A, Seyedpour N, Yazdi M Vaccines (Basel). 2023; 11(1).

PMID: 36679991 PMC: 9866612. DOI: 10.3390/vaccines11010146.

Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Li Z, Yang D, Guo T, Lin M Biomolecules. 2022; 12(7).

PMID: 35883508 PMC: 9313386. DOI: 10.3390/biom12070952.

References

Bitler B, Goverdhan A, Schroeder J . MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010; 123(Pt 10):1716-23. PMC: 2864713. DOI: 10.1242/jcs.062661. View

Li Y, Cozzi P . MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets. 2007; 7(3):259-71. DOI: 10.2174/156800907780618338. View

Walsh M, Luckie S, Cummings M, Antalis T, McGuckin M . Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res Treat. 2000; 58(3):255-66. DOI: 10.1023/a:1006345301364. View

Thathiah A, Carson D . MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J. 2004; 382(Pt 1):363-73. PMC: 1133949. DOI: 10.1042/BJ20040513. View

Ciborowski P, Finn O . Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis. 2002; 19(4):339-45. DOI: 10.1023/a:1015590515957. View

Rajabi H, Kufe D . MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta Rev Cancer. 2017; 1868(1):117-122. PMC: 5548633. DOI: 10.1016/j.bbcan.2017.03.003. View

Acres B, Limacher J . MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines. 2005; 4(4):493-502. DOI: 10.1586/14760584.4.4.493. View

Apostolopoulos V, Stojanovska L, Gargosky S . MUC1 (CD227): a multi-tasked molecule. Cell Mol Life Sci. 2015; 72(23):4475-500. PMC: 11113675. DOI: 10.1007/s00018-015-2014-z. View

Li Y, Bharti A, Chen D, Gong J, Kufe D . Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol. 1998; 18(12):7216-24. PMC: 109303. DOI: 10.1128/MCB.18.12.7216. View

10.

Ibrahim N, Yariz K, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A . Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res. 2011; 17(21):6822-30. DOI: 10.1158/1078-0432.CCR-11-1151. View

11.

Thathiah A, Blobel C, Carson D . Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem. 2002; 278(5):3386-94. DOI: 10.1074/jbc.M208326200. View

12.

Liu X, Caffrey T, Steele M, Mohr A, Singh P, Radhakrishnan P . MUC1 regulates cyclin D1 gene expression through p120 catenin and β-catenin. Oncogenesis. 2014; 3:e107. PMC: 4150213. DOI: 10.1038/oncsis.2014.19. View

13.

Piyush T, Chacko A, Sindrewicz P, Hilkens J, Rhodes J, Yu L . Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. Cell Death Differ. 2017; 24(11):1937-1947. PMC: 5635220. DOI: 10.1038/cdd.2017.119. View

14.

Regimbald L, Pilarski L, Longenecker B, Reddish M, Zimmermann G, Hugh J . The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 1996; 56(18):4244-9. View

15.

Bitler B, Menzl I, Huerta C, Sands B, Knowlton W, Chang A . Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res. 2009; 15(1):100-9. PMC: 2676873. DOI: 10.1158/1078-0432.CCR-08-1745. View

16.

Smagghe B, Stewart A, Carter M, Shelton L, Bernier K, Hartman E . MUC1* ligand, NM23-H1, is a novel growth factor that maintains human stem cells in a more naïve state. PLoS One. 2013; 8(3):e58601. PMC: 3591366. DOI: 10.1371/journal.pone.0058601. View

17.

Kufe D . MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2012; 32(9):1073-81. PMC: 3621754. DOI: 10.1038/onc.2012.158. View

18.

Bouillez A, Adeegbe D, Jin C, Hu X, Tagde A, Alam M . MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. Oncoimmunology. 2017; 6(9):e1338998. PMC: 5599083. DOI: 10.1080/2162402X.2017.1338998. View

19.

Farahmand L, Merikhian P, Jalili N, Darvishi B, Majidzadeh-A K . Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents. Curr Cancer Drug Targets. 2017; 18(8):737-748. DOI: 10.2174/1568009617666170623113520. View

20.

Mahanta S, Fessler S, Park J, Bamdad C . A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One. 2008; 3(4):e2054. PMC: 2329594. DOI: 10.1371/journal.pone.0002054. View